(0)
CHICAGO, April 14, 2021 /PRNewswire/ In-depth analysis and data-driven insights on the impact of COVID-19 included in this global vaccine contract manufacturing market report.
The vaccine contract manufacturing market is expected to grow at a CAGR of approximately 13% during the period 2020-2026.
Key Highlights Offered in the Report:
The global vaccine contract manufacturing market is expected to grow with an incremental growth of around USD 2 billion and absolute growth of around 104% during the forecast period.
In scale of operation, the commercial segment has the highest share of around 64% due to high uptake of vaccines as well as growing vaccine pipeline and is likely to witness highest incremental growth of around USD 1.3 billion during the forecast period.
04.08.21 Regulatory, Legislative Actions Set The Tone For Biosimilars In 2021
On this episode of the
Business of Biotech, Nevan Charles Elam, J.D., founder of Rezolute Bio, shares the company s rationale for pursuing congenital hyperinsulinism and diabetic macular edema therapeutics by leveraging monoclonal antibodies and discusses the company s approach to process development and manufacturing. Listen now and subscribe so you never miss an episode.
Featured Editorial
By Philip Chen, Kayleigh McGlynn, and Jenny Shmuel, Fish & Richardson P.C.
This article focuses on regulatory and legislative actions in 2020 that may impact the burgeoning biosimilars space in 2021 and beyond. In particular, the authors revisit the implications of the March 23, 2020, transition date, as well as the FDA’s efforts to address biosimilar competition, interchangeability, and the COVID-19 pandemic.
Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
This report features an extensive study of the current market landscape and the future potential of sterile fill/finish services for small molecule drugs. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.
Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In fact, in 2019, the FDA s Center for Drug Evaluation and Research approved 48 small molecule drugs, representing 70% of the new molecular entities (NMEs) clearing regulatory review in the same year. Given that the demand for small molecule drugs is still on the rise, the importance of contract manufacturing and third party services is also increasing in the pharmaceutical industry. Sterile fill/finish is considered among the most crucial steps in the pharmaceutical production process. In fact, aseptic conditions during fill/finish operations are not only esse